TRIB20260918P7.5
TRIB Sep 18 2026 7.50 Put (TRIB260918P00007500)
option OPRA

since its formation in 1992, trinity biotech has actively pursued the aim of becoming a leading player in the international diagnostics industry. through a combination of sustained, organic growth and an acquisition-led strategy, the company has assembled an impressive product portfolio and achieved the highest standards of excellence in developing, manufacturing and marketing diagnostic products. the test kits manufactured by trinity biotech are used in the clinical laboratory and point-of-care segments of the diagnostic market to detect infectious diseases, sexually transmitted diseases, autoimmune and haemoglobin disorders, and detect, monitor and control diabetes. the company is also a significant provider of raw materials to the life sciences industry. trinity biotech, which has its headquarters in ireland, employs in excess of 350 people and markets its portfolio of over 400 products to customers in 80 countries around the world. it reaches this worldwide market by combining the